SEQUENCE LISTING <110> Chimienti et al. <120> SLURP-1 Compositions and Methods of Use Thereof <130> 20349-564 <140> 10/826,788 <141> 2004-04-16 <150> 60/463,418 <151> 2003-04-16 <160> 6 <170> PatentIn Ver. 2.1 <210> 1 <211> 8 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: Consensus Domain Sequence <220> <221> VARIANT <222> (3)..(6) <223> Wherein Xaa is any amino acid. <400> 1 Cys Cys Xaa Xaa Xaa Cys Asn 5 <210> 2 <211> 103 <212> PRT <213> Homo sapiens <400> 2 Met Ala Ser Arg Trp Ala Val Gln Leu Leu Val Ala Ala Trp Ser 5

Met Gly Cys Gly Glu Ala Leu Lys Cys Tyr Thr Cys Lys Glu Pro Met

Thr Ser Ala Ser Cys Arg Thr Ile Thr Arg Cys Lys Pro Glu Asp Thr

Ala Cys Met Thr Thr Leu Val Thr Val Glu Ala Glu Tyr Pro Phe Asn 50 55

Gln Ser Pro Val Val Thr Arg Ser Cys Ser Ser Cys Val Ala Thr 70 75

_	- 8	35	90		. 1	95	J
Asp Le	eu Cys Asn Se 100	er Glu Leu					
<210><211><212><213>	27	Sequence					
<220> <223>	Description Sequence	of Artificial	Sequence:	Primer			
<400> aagctt	3 :ggag caatggo	cete tegetgg					27
<210><211><212><213>	27	Sequence					
<220> <223>	Description Sequence	of Artificial	Sequence:	Primer			
<400> tctaga	4 agagt teegagt	tgc agaggtc					27
<210><211><212><213>	20	Sequence					
<220> <223>	Description Sequence	of Artificial	Sequence:	Primer			
<400> gagata	5 atcgg agcaato	ggcc					20
<210><211><212><212><213>	30	Sequence					
<220> <223>	Description Sequence	of Artificial	Sequence:	Primer			
<400>	6						

Asp Pro Asp Ser Ile Gly Ala Ala His Leu Ile Phe Cys Cys Phe Arg